BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35460613)

  • 1. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
    Hodder AN; Christensen J; Scally S; Triglia T; Ngo A; Birkinshaw RW; Bailey B; Favuzza P; Dietrich MH; Tham WH; Czabotar PE; Lowes K; Guo Z; Murgolo N; Lera Ruiz M; McCauley JA; Sleebs BE; Olsen D; Cowman AF
    Structure; 2022 Jul; 30(7):947-961.e6. PubMed ID: 35460613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
    Favuzza P; de Lera Ruiz M; Thompson JK; Triglia T; Ngo A; Steel RWJ; Vavrek M; Christensen J; Healer J; Boyce C; Guo Z; Hu M; Khan T; Murgolo N; Zhao L; Penington JS; Reaksudsan K; Jarman K; Dietrich MH; Richardson L; Guo KY; Lopaticki S; Tham WH; Rottmann M; Papenfuss T; Robbins JA; Boddey JA; Sleebs BE; Sabroux HJ; McCauley JA; Olsen DB; Cowman AF
    Cell Host Microbe; 2020 Apr; 27(4):642-658.e12. PubMed ID: 32109369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man.
    Li T; Yowell CA; Beyer BB; Hung SH; Westling J; Lam MT; Dunn BM; Dame JB
    Mol Biochem Parasitol; 2004 May; 135(1):101-9. PubMed ID: 15287591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
    Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
    Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.
    Richardson LW; Ashton TD; Dans MG; Nguyen N; Favuzza P; Triglia T; Hodder AN; Ngo A; Jarman KE; Cowman AF; Sleebs BE
    ChemMedChem; 2022 Sep; 17(18):e202200306. PubMed ID: 35906744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress.
    Pino P; Caldelari R; Mukherjee B; Vahokoski J; Klages N; Maco B; Collins CR; Blackman MJ; Kursula I; Heussler V; Brochet M; Soldati-Favre D
    Science; 2017 Oct; 358(6362):522-528. PubMed ID: 29074775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.
    de Lera Ruiz M; Favuzza P; Guo Z; Zhao L; Hu B; Lei Z; Zhan D; Murgolo N; Boyce CW; Vavrek M; Thompson J; Ngo A; Jarman KE; Robbins J; Boddey J; Sleebs BE; Lowes KN; Cowman AF; Olsen DB; McCauley JA
    ACS Med Chem Lett; 2022 Nov; 13(11):1745-1754. PubMed ID: 36385924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole.
    Luker KE; Francis SE; Gluzman IY; Goldberg DE
    Mol Biochem Parasitol; 1996 Jul; 79(1):71-8. PubMed ID: 8844673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
    Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF
    Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping selectivity and specificity of active site of plasmepsins from Plasmodium falciparum using molecular interaction field approach.
    Kumar A; Ghosh I
    Protein Pept Lett; 2007; 14(6):569-74. PubMed ID: 17627598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.
    Li F; Bounkeua V; Pettersen K; Vinetz JM
    Malar J; 2016 Feb; 15():111. PubMed ID: 26911483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
    Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
    Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and modelling of photoreactive chemical probes for investigating target engagement of plasmepsin IX and X in
    Lisauskaitė M; Nixon GL; Woodley CM; Berry NG; Coninckx A; Qie LC; Leung SC; Taramelli D; Basilico N; Parapini S; Ward SA; Vadas O; Soldati-Favre D; Hong WD; O'Neill PM
    RSC Chem Biol; 2024 Jan; 5(1):19-29. PubMed ID: 38179191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bridging the Gap in Malaria Parasite Resistance, Current Interventions, and the Way Forward from in Silico Perspective: A Review.
    Kumi RO; Oti B; Abo-Dya NE; Alahmdi MI; Soliman MES
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
    Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
    J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling and resistant alleles explain the selectivity of antimalarial compound 49c towards apicomplexan aspartyl proteases.
    Mukherjee B; Tessaro F; Vahokoski J; Kursula I; Marq JB; Scapozza L; Soldati-Favre D
    EMBO J; 2018 Apr; 37(7):. PubMed ID: 29519896
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical characterization of plasmepsin V from Plasmodium vivax Thailand isolates: Substrate specificity and enzyme inhibition.
    Sappakhaw K; Takasila R; Sittikul P; Wattana-Amorn P; Assavalapsakul W; Boonyalai N
    Mol Biochem Parasitol; 2015 Dec; 204(2):51-63. PubMed ID: 26795263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flap flexibility amongst plasmepsins I, II, III, IV, and V: Sequence, structural, and molecular dynamics analyses.
    McGillewie L; Soliman ME
    Proteins; 2015 Sep; 83(9):1693-705. PubMed ID: 26146842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent
    Kovada V; Withers-Martinez C; Bobrovs R; Ce Rule HN; Liepins E; Grinberga S; Hackett F; Collins CR; Kreicberga A; Jiménez-Díaz MB; Angulo-Barturen I; Rasina D; Suna E; Jaudzems K; Blackman MJ; Jirgensons A
    J Med Chem; 2023 Aug; 66(15):10658-10680. PubMed ID: 37505188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.
    Liu P; Marzahn MR; Robbins AH; Gutiérrez-de-Terán H; Rodríguez D; McClung SH; Stevens SM; Yowell CA; Dame JB; McKenna R; Dunn BM
    Biochemistry; 2009 May; 48(19):4086-99. PubMed ID: 19271776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.